Please Wait

Applying Filters...

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER
KDMF
Table View

Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

31 API Suppliers, 13 USDMF, 14 CEP/COS, 4 EU WC, 1 KDMF, 1 NDC API, 12 Listed Suppliers, $ API Reference Price

FINISHED DOSAGE FORMULATIONS

230 FDF Dossiers, 35 FDA Orange Book, 85 Europe, 2 Canada, 8 Australia, 52 South Africa, 48 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 7.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAMUSCULAR, INTRAVENOUS - EQ 750MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 30MG BASE/ML

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma, 1 Actylis, 1 Kerry, 1 Microlex e.U, 1 Pluviaendo, 1 Roquette

EXCIPIENTS BY APPLICATIONS

4 Parenteral, 2 Fillers, Diluents & Binders, 1 Chewable & Orodispersible Aids, 1 Taste Masking

DIGITAL CONTENT

1 News #PharmaBuzz

1 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 22 Regulatory FDF Prices

MARKET PLACE

12 APIs, 5 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 EDQM, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Kyongbo Pharmaceutical Co., Ltd	South Korea	Kyungbo Pharmaceutical Co., Ltd.	20190102-210-J-292	cefuroxime sodium	2019-01-02	Kyungbo Pharmaceutical Co., Ltd. @ [Starting material: Cefuroxime manufacturing plant] Sinopharm Weiqida Pharmaceutical Co., Ltd	South Korea	174 Silok-ro, Asan-si, Chungcheongnam-do @ [Starting material: Cefuroxime manufacturing plant] Economic & Technological Development Zone, First Medical Zone, Datong, Shanxi China

Contact us
to update this info

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

31 API Suppliers

13 USDMF

14 CEP/COS

4 EU WC

1 KDMF

1 NDC API

12 Listed Suppliers

$ API Reference Price

FINISHED DOSAGE FORMULATIONS

230 FDF Dossiers

35 FDA Orange Book

85 Europe

2 Canada

8 Australia

52 South Africa

48 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 7.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS - EQ 750MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 30MG BASE/ML

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma

1 Actylis

1 Kerry

1 Microlex e.U

1 Pluviaendo

1 Roquette

EXCIPIENTS BY APPLICATIONS

4 Parenteral

2 Fillers, Diluents & Binders

1 Chewable & Orodispersible Aids

1 Taste Masking

DIGITAL CONTENT

1 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

22 Regulatory FDF Prices

MARKET PLACE

12 APIs

5 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 EDQM

1 Others

ANALYTICAL

1 BioAnalytical Methods

Filters

INJECTABLE;INJECTION - EQ 1.5GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 7.5GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS - EQ 750MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons